8-K ·Filed Apr 21, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Monitor upcoming 10-Q for any changes in financial guidance or capital structure that may have prompted the CFO transition. The internal promotion of Swartz suggests continuity in financial leadership.
Final — all horizons settled through T+60d
VYGR ▼ -23.43% at T+60d
NEUTRAL call -23.43% · α vs SPY -28.21% · entry $4.14 → $3.17
T+1d
-2.42%
call -2.42% · α -2.02%
$4.04
settled 6mo ago
T+5d
-9.66%
call -9.66% · α -9.72%
$3.74
settled 6mo ago
T+20d
-15.94%
call -15.94% · α -19.11%
$3.48
settled 5mo ago
T+60d
-23.43%
call -23.43% · α -28.21%
$3.17
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Voyager Therapeutics CFO Nathan Jorgensen resigned to pursue a new opportunity, with no disagreement cited. Robin Swartz and Amy Quinlan were appointed as principal financial officer/treasurer and principal accounting officer, respectively, effective May 8, 2026.
Key Facts
- CFO Nathan Jorgensen resigned effective May 8, 2026, to pursue a new opportunity
- Resignation was not due to any disagreement with the company
- Robin Swartz appointed principal financial officer and treasurer, effective May 8, 2026
- Amy Quinlan appointed principal accounting officer, effective May 8, 2026
- Swartz has held multiple executive roles at Voyager since 2021, including prior stints as CFO and COO
- Quinlan has served as VP of Finance since January 2025
Financial Impact
No immediate financial impact disclosed
leadershipgovernance
Risk Factors
- Potential disruption during CFO transition period
- Market perception of executive turnover in a small-cap biotech
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-045997 |
| Document: 0001104659-26-045997-index-headers.html | 0001104659-26-045997 |
| Document: 0001104659-26-045997-index.html | 0001104659-26-045997 |
| Document: 0001104659-26-045997.txt | 0001104659-26-045997 |
9 reports for VYGR
40% Hit rate @ T+60 Went positive at some point 3 of 5 best @ T+60▲ +7.94%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.02 | awaiting T+60 | — | $1.79 (−11.39%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.79 (−44.75%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.79 (−52.77%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.79 (−56.87%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.79 (−55.80%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.79 (−52.52%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.79 (−56.76%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
Showing 9 of 9
US Market Status
Market Open — Closes in 4h 28m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers